Bobby Johnson, MD
Endocrinology, Diabetes & Metabolism · Huntsville, ALNPI 1285683649
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,250 of the $4,124 with a category attached, or 78.8%. It is spread thinly across 22 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 250 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$988
- Tandem Diabetes Care, Inc.$850
- Dexcom, Inc.$660
- Novo Nordisk$648
- Abbott$278
- Xeris Pharmaceuticals, Inc.$188
- plus $511 from 16 others
What the payments were for
- Speaking & faculty fees$85021%
- Food & beverage$3,25079%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 79 | $988 |
| Tandem Diabetes Care, Inc. | 3 | $850 |
| Dexcom, Inc. | 45 | $660 |
| Novo Nordisk | 67 | $648 |
| Abbott | 19 | $278 |
| Xeris Pharmaceuticals, Inc. | 9 | $188 |
| Lilly USA, LLC | 4 | $72 |
| BETA Bionics, Inc. | 4 | $72 |
| Bayer | 3 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Amgen | 2 | $39 |
| Corcept Therapeutics | 2 | $34 |
| Chiesi USA, Inc. | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Novartis | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| AstraZeneca | 1 | $18 |
| Insulet Corporation | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $13 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,124 in reported general payments places this provider in the 35th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 475 | $632,256 |
| MounjaroTirzepatide | 357 | $477,185 |
| JardianceEmpagliflozin | 404 | $446,956 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 137 | $216,515 |
| Tresiba Flextouch U-100Insulin Degludec | 222 | $168,403 |
| Humalog Kwikpen U-100Insulin Lispro | 392 | $156,450 |
| JanuviaSitagliptin Phosphate | 150 | $137,174 |
| Tresiba Flextouch U-200Insulin Degludec | 89 | $128,860 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 148 | $124,782 |
| Novolog FlexpenInsulin Aspart | 307 | $120,724 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 72 | $90,870 |
| FarxigaDapagliflozin Propanediol | 73 | $80,397 |
| JanumetSitagliptin Phos/Metformin Hcl | 67 | $77,689 |
| RybelsusSemaglutide | 47 | $74,443 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $71,287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $648 | $763,918656 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin N | $72 | $570,844596 claims |
| AstraZenecaFarxiga | $18 | $80,39773 claims |
| AbbVieSynthroid | $12 | $21,274230 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $15,1901,062 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Huntsville
- Dwain WoodeHuntsville$78K
- Ankur JindalHuntsville$6K
- Malapuram Vasudha ReddyHuntsville$6K
- Joshua TateHuntsville$5K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.